Improving response and outcomes for patients with liver-limited metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 9, Issue SUPPL.1, 2010, Pages

  Gallagher, David J ^a   Kemeny, Nancy ^a,b  

^a Gastrointestinal Oncology Solid Tumor Service   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bevacizumab; Cetuximab; FOLFOX; Hepatic arterial infusion; Irinotecan; Neoadjuvant chemotherapy; Panitumumab; Perioperative therapy; Radiofrequency ablation

Indexed keywords

BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; HUMAN; LIVER METASTASIS; PERIOPERATIVE PERIOD; RADIOFREQUENCY ABLATION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ANIMAL; COLORECTAL NEOPLASMS; LIVER NEOPLASMS; LIVER RESECTION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOTHERAPY; SECONDARY; TOTAL QUALITY MANAGEMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; QUALITY IMPROVEMENT; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 84860564185     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.3816/CCC.2010.s.005     Document Type: Article

References (88)

1. Paku S, Dome B, Toth R, et al. Organ-specificity of the extravasation process: an ultrastructural study. Clin Exp Metastasis 2000; 18:481-92. (Pubitemid 32844249)
2. Lalor PF, Lai WK, Curbishley SM, et al. Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J Gastroenterol 2006; 12:5429-39. (Pubitemid 44501799)
3. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133:571-3.
4. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980; 40:2281-7. (Pubitemid 10082239)
5. Fidler IJ, Poste G. The "seed and soil" hypothesis revisited. Lancet Oncol 2008; 9:808.
6. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organspecific colonization. Nat Rev Cancer 2009; 9:274-84.
7. Chambers AF, Groom AC, MacDonald IC. Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2:563-72. (Pubitemid 37328923)
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
9. Thompson EW, Newgreen DF. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005; 65:5991-5. (Pubitemid 40994377)
10. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005; 11:8006-14. (Pubitemid 41698741)
11. Tarin D. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005; 65:5996-6001.
12. Gallagher DJ, Milowsky MI, Ishill N, et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol 2009; 20:305-8.
13. Cohen SJ, Alpaugh RK, Gross S, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:125-32. (Pubitemid 44445747)
14. Klein CA. The systemic progression of human cancer: a focus on the individual disseminated cancer cell-the unit of selection. Adv Cancer Res 2003; 89:35-67. (Pubitemid 41184279)
15. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8:341-52. (Pubitemid 46625811)
16. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-6. (Pubitemid 32225831)
17. Hiratsuka S, Watanabe A, Aburatani H, et al. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8:1369-75. (Pubitemid 44835111)
18. Hiratsuka S, Watanabe A, Sakurai Y, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008; 10:1349-55.
19. Nelson CM, Bissell MJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2006; 22:287-309.
20. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6:24-37. (Pubitemid 43053650)
21. Katz SC, Pillarisetty V, Bamboat ZM, et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 2009; 16:2524-30.
22. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254-65. (Pubitemid 34189413)
23. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 2003; 100:7737-42. (Pubitemid 36760039)
24. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer [published correction appears in N Engl J Med 2000; 343:308]. N Engl J Med 2000; 342:525-33. (Pubitemid 30117892)
25. Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13:58-68. (Pubitemid 350309740)
26. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-53.
27. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005; 7:513-20. (Pubitemid 40799245)
28. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70:163-9. (Pubitemid 16140378)
29. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26:1635-41.
30. Gallagher DJ, Zheng J, Capanu M, et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009; 16:1844-51.
31. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240:644-57.
32. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235:759-66. (Pubitemid 34547293)
33. Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13:1271-80. (Pubitemid 44435793)
34. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-53. (Pubitemid 32422861)
35. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-9. (Pubitemid 29342371)
36. Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005; 16:425-9. (Pubitemid 40458319)
37. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15:933-9. (Pubitemid 39004350)
38. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23:9243-9.
39. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670-6. (Pubitemid 46797946)
40. Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/ leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008; 62:195-201. (Pubitemid 351692073)
41. Okines A, del Puerto O, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO 16966 trial. Br J Cancer 2009; 101:1033-8.
42. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20:1842-7.
43. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin- based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study [published corrections appear in J Clin Oncol 2009; 27:653 and J Clin Oncol 2008; 26: 3110]. J Clin Oncol 2008; 26:2013-9.
44. Van Cutsem E, Kohne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17.
45. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11:38-47.
46. Kemeny NE, Huitzil Melendez FD, Capanu M, et al. Conversion to respectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27:3465-71.
47. Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007; 25(suppl):962s (abstract LBA5).
48. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371:1007-16. (Pubitemid 351392040)
49. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26:4906-11.
50. Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20:1964-70.
51. Vauthey J-N, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065-72. (Pubitemid 46622116)
52. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7:1034-44. (Pubitemid 37524071)
53. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24:4983-90. (Pubitemid 46631400)
54. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249:420-5.
55. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 2009; 27(18 suppl): (abstract LBA4).
56. Klinger M, Eipeldauer S, Hacker S, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009; 35:515-20.
57. Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007; 14:1151-60.
58. Bathe OF, Ernst S, Sutherland FR, et al. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer 2009; 9:156.
59. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300:2277-85.
60. Petrelli NJ. Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin Oncol 2008; 26:4862-3.
61. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189:291-9. (Pubitemid 29408866)
62. Wang X, Hershman DL, Abrams JA, et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer 2007; 97:1606-12. (Pubitemid 350249362)
63. Ychou M, Raoul J-L, Douillard J-Y, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009; 20:674-80.
64. Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007; 204:753-61. (Pubitemid 46661187)
65. Tanaka K, Shimada H, Ueda M, et al. Role of hepatectomy in treating multiple bilobar colorectal cancer metastases. Surgery 2008; 143:259-70.
66. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228:756-62. (Pubitemid 30191686)
67. Lygidakis NJ, Sgourakis G, Dedemadi G, et al. Regional chemoimmunotherapy for nonresectable metastatic liver disease of colorectal origin. A prospective randomized study. Hepatogastroenterology 2001; 48:1085-7. (Pubitemid 32757750)
68. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-48. (Pubitemid 30035952)
69. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352:734-5. (Pubitemid 40239230)
70. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for respectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002; 20:1499-505. (Pubitemid 34260528)
71. Kemeny N, Capanu M, D'Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009; 20:1236-41.
72. Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005; 201:57-65. (Pubitemid 40840564)
73. Scaife CL, Curley SA, Izzo F, et al. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol 2003; 10:348-54. (Pubitemid 40486930)
74. Stang A, Fischbach R, Teichmann W, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009; 45:1748-56.
75. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28:493-508.
76. Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009; CD007045.
77. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR Spheres *plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88:78-85. (Pubitemid 39536508)
78. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres * plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12:1711-20. (Pubitemid 34105661)
79. Small RM, Lubezky N, Shmueli E, et al. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 2009; 99:93-8.
80. Blazer DG III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 25:5344-51.
81. Chiappa A, Bertani E, Makuuchi M, et al. Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepatogastroenterology 2009; 56:829-34.
82. Gallagher DJ, Kemeny NE. Colorectal hepatic metastases: adjuvant chemotherapy and survival. J Clin Oncol 2009; 27:e18-9.
83. Boostrom SY, Nagorney DM, Donohue JH, et al. Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases. J Gastrointest Surg 2009; 13:2003-9.
84. Chua TC, Saxena A, Liauw W, et al. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 2010; 17:492-501.
85. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939-45. (Pubitemid 46630742)
86. Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116:1502-9.
87. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14:3188-94. (Pubitemid 47594272)
88. Chun YS, Vauthey J-N, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302:2338-44.